Artelo Biosciences Announces Positive Preclinical Efficacy Data for ART26.12 in Osteoarthritis Pain at the 35th Annual International Cannabinoid Research Society Symposium

ART26.12, a Novel FABP5 Inhibitor, Demonstrates Sustained Analgesic Effects Without Tolerance

Excerpt from the Press Release:

SOLANA BEACH, Calif., July 09, 2025 (GLOBE NEWSWIRE) — Artelo Biosciences, Inc. (Nasdaq: ARTL), a clinical-stage pharmaceutical company focused on modulating lipid-signaling pathways to develop treatments for people living with cancer, pain, dermatological or neurological conditions, today announced the presentation of preclinical data in an osteaoarthritis (OA) pain model on its lead fatty acid binding protein 5 (FABP5) inhibitor, ART26.12, at the 35^th Annual International Cannabinoid Research Society (ICRS) Symposium, being held July 6–10 in Bloomington, Indiana.

The presentation, titled “The Fatty Acid Binding Protein 5 Inhibitor ART26.12 Alleviates Osteoarthritis Pain,” was delivered on July 8th by Dr. Martin Kaczocha, Assistant Professor in the Departments of Anesthesiology, Biochemistry and Cell Biology at Stony Brook University, New York. Dr. Kaczocha was the lead researcher for the OA study and serves as a scientific advisor at Artelo. The results demonstrated that ART26.12, a first-in-class, non-opioid, non-steroidal analgesic drug candidate, significantly alleviated pain associated with OA in preclinical models, in which a direct effect on plasma levels of relevant endocannabinoids was also observed.

“We are grateful to continue our translational research with ART26.12 in OA models in collaboration with Stony Brook University,” commented Professor Saoirse O’Sullivan, Vice President of Translation Sciences at Artelo. “Our latest data now shows in this OA model that daily treatment with ART26.12 leads to increases in plasma levels of the endocannabinoids 2-Arachidonoylglycerol (2-AG) and Oleoylethanolamide (OEA).

Click the button below to read the entire Press Release:

Continue Reading The Press Release